
Indivior Appoints Daniel A. Ninivaggi to the Board
Mr. Ninivaggi has significant public company experience as a director and executive and brings to Indivior a strong background in operations and capital allocation, as well as legal and finance expertise.
Mr. Ninivaggi has also been appointed a member of the Nomination Committee.
Comment by Dr. David Wheadon, Chair
"I am pleased to announce Dan's appointment to the Board. As a seasoned public company executive, we are delighted that Indivior will be able to benefit from his significant board and operational experience as we work together to deliver value to all Indivior stakeholders."
Comment by Daniel Ninivaggi
"I welcome the opportunity to join the Board of Indivior. I believe Indivior has an important mission in helping to transform the lives of patients struggling with opioid use disorder. I look forward to working closely with the Board and management team to realize Indivior's full potential as a global leader in developing and commercializing novel opioid use disorder treatments."
Daniel Ninivaggi Biography
Daniel A. Ninivaggi is currently Chairman of Garrett Motion Inc. (NASDAQ:GTX), a
Mr. Ninivaggi has served as a director of numerous public and private companies, including Garrett Motion Inc., Lordstown Motors Corp., Hertz Global Holdings Inc., Navistar International Corporation, Icahn Enterprises G.P. Inc. (the general partner of Icahn Enterprises), CVR Energy Inc., LLC, XO Holdings, Tropicana Entertainment Inc., Motorola Mobility Holdings Inc., and CIT Group, Inc.
Mr. Ninivaggi began his career at Skadden, Arps, Slate, Meagher & Flom LLP before joining Winston & Strawn LLP, where he became a partner specializing in mergers & acquisitions, financing transactions and corporate governance. . He holds a Bachelor of Arts degree from
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
For Further Information
Investor Enquiries |
Jason Thompson |
VP, Investor Relations Indivior PLC |
+1 804 402 7123 jason.thompson@indivior.com |
|
Tim Owens |
Director, Investor Relations Indivior PLC |
+1 804 263 3978 timothy.owens@indivior.com |
Media Enquiries |
Jonathan Sibun
|
Teneo
|
+44 (0)20 7353 4200
+1 804 594 0836 Indiviormediacontacts@indivior.com |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.